Patents by Inventor David T. MacLaughlin
David T. MacLaughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9791449Abstract: The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad? subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad? ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.Type: GrantFiled: June 1, 2012Date of Patent: October 17, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Patricia K. Donahoe, David T. MacLaughlin, Jose Teixeira
-
Patent number: 9289492Abstract: The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.Type: GrantFiled: July 17, 2008Date of Patent: March 22, 2016Assignee: The General Hospital CorporationInventors: Patricia K Donahoe, Paul P Szotek, David T MacLaughlin, Frederic Preffer, Rafael Pieretti-Vanmarcke, David Michael Dombkowski
-
Publication number: 20140194366Abstract: The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad? subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad? ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.Type: ApplicationFiled: June 1, 2012Publication date: July 10, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Patricia K. Donahoe, David T. MacLaughlin, Jose Teixeira
-
Publication number: 20100273160Abstract: The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.Type: ApplicationFiled: July 17, 2008Publication date: October 28, 2010Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Patricia K. Donahoe, Paul P. Szotek, David T. MacLaughlin, Frederic Preffer, Rafael Pieretti-Vanmarcke, David Michael Dombkowski
-
Patent number: 7427486Abstract: Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response to fertility treatment. The MIS levels can be monitored prior to and during fertility treatment and are useful to adjust the timing and dosage of treatments in order to produce optimal outcome in individual patients, to avoid ovarian hyperstimulation, or to indicate cancellation of an unsuccessful treatment. MIS can also be administered to women to stimulate follicle development and to prevent depletion of ovarian reserve.Type: GrantFiled: June 29, 2007Date of Patent: September 23, 2008Assignees: University of Medicine and Dentistry of New Jersey, The General Hospital CorporationInventors: David B. Seifer, David T. MacLaughlin
-
Patent number: 7241577Abstract: Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response to fertility treatment. The MIS levels can be monitored prior to and during fertility treatment and are useful to adjust the timing and dosage of treatments in order to produce optimal outcome in individual patients, to avoid ovarian hyperstimulation, or to indicate cancellation of an unsuccessful treatment. MIS can also be administered to women to stimulate follicle development and to prevent depletion of ovarian reserve.Type: GrantFiled: August 20, 2002Date of Patent: July 10, 2007Assignees: University of Medicine and Dentistry of New Jersey, The General Hospital CorporationInventors: David B. Seifer, David T. MacLaughlin
-
Patent number: 7078032Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.Type: GrantFiled: October 21, 2003Date of Patent: July 18, 2006Assignee: The General Hospital CorporationInventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
-
Publication number: 20040086497Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.Type: ApplicationFiled: October 21, 2003Publication date: May 6, 2004Inventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
-
Patent number: 6692738Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.Type: GrantFiled: January 26, 2001Date of Patent: February 17, 2004Assignee: The General Hospital CorporationInventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
-
Publication number: 20020031500Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.Type: ApplicationFiled: January 26, 2001Publication date: March 14, 2002Inventors: David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
-
Patent number: 5661126Abstract: This application concerns the treatment of certain tumors using an effective amount of the glycoprotein Mullerian Inhibiting Substance (MIS). This application further concerns the treatment of certain tumors using an effective amount of the C-terminal fragment of MIS. Also, this application concerns DNA sequences encoding the C-terminal fragment of MIS, vectors containing the DNA sequence and transformed host cells capable of producing the C-terminal fragment. This application further concerns treating certain tumors by transfecting tumor cells with a gene coding for MIS or the C-terminal fragment of MIS. Gene therapy treatments for inhibiting growth of certain tumors are also provided. Further, this application concerns a method for modulating class I histocompatibility antigens with MIS and EGF.Type: GrantFiled: July 7, 1994Date of Patent: August 26, 1997Assignee: The General Hospital CorporationInventors: Patricia K. Donahoe, Tai Wai Chin, Robert L. Parry, James Epstein, Richard C. Ragin, David T. MacLaughlin, Edward M. Barksdale